DK3256466T3 - 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser - Google Patents

1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser Download PDF

Info

Publication number
DK3256466T3
DK3256466T3 DK16708262.7T DK16708262T DK3256466T3 DK 3256466 T3 DK3256466 T3 DK 3256466T3 DK 16708262 T DK16708262 T DK 16708262T DK 3256466 T3 DK3256466 T3 DK 3256466T3
Authority
DK
Denmark
Prior art keywords
isochromanyl
heterocyclyl
analogs
compounds
treatment
Prior art date
Application number
DK16708262.7T
Other languages
Danish (da)
English (en)
Inventor
Linghong Xie
Philip Glyn Jones
Kerry L Spear
Noel Aaron Powell
Taleen G Hanania
Vadim Alexandrov
Original Assignee
Sunovion Pharmaceuticals Inc
Pgi Drug Discovery Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc, Pgi Drug Discovery Llc filed Critical Sunovion Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3256466T3 publication Critical patent/DK3256466T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16708262.7T 2015-02-11 2016-02-11 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser DK3256466T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Publications (1)

Publication Number Publication Date
DK3256466T3 true DK3256466T3 (da) 2022-05-02

Family

ID=55456908

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16708262.7T DK3256466T3 (da) 2015-02-11 2016-02-11 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser

Country Status (22)

Country Link
US (4) US9856238B2 (enExample)
EP (2) EP4046995B1 (enExample)
JP (3) JP6657241B2 (enExample)
KR (1) KR102601972B1 (enExample)
CN (2) CN111925360B (enExample)
AU (1) AU2016219253C1 (enExample)
CA (1) CA2976095C (enExample)
CY (1) CY1125198T1 (enExample)
DK (1) DK3256466T3 (enExample)
EA (1) EA201791804A1 (enExample)
ES (2) ES2967643T3 (enExample)
HU (1) HUE058698T2 (enExample)
IL (1) IL253914B (enExample)
MX (2) MX392664B (enExample)
MY (1) MY188160A (enExample)
NZ (1) NZ735011A (enExample)
PH (1) PH12017501422A1 (enExample)
PL (1) PL3256466T3 (enExample)
PT (1) PT3256466T (enExample)
SG (2) SG10201806809QA (enExample)
UA (1) UA122222C2 (enExample)
WO (1) WO2016130796A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс
US9758529B2 (en) * 2015-02-11 2017-09-12 Sunovion Pharmaceuticals Inc. Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018258117A1 (en) 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
EP1089993B1 (en) 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
CA2465186A1 (en) * 2001-11-08 2003-05-15 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
WO2006066756A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
KR20080090545A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Cns 장애 치료용 2-이미다졸의 용도
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
CN104193761B (zh) * 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс

Also Published As

Publication number Publication date
CN111925360A (zh) 2020-11-13
US11192885B2 (en) 2021-12-07
US20180093974A1 (en) 2018-04-05
KR20170129730A (ko) 2017-11-27
MX392664B (es) 2025-03-24
PH12017501422A1 (en) 2018-03-19
PT3256466T (pt) 2022-05-10
AU2016219253C1 (en) 2022-12-08
US20170001987A1 (en) 2017-01-05
JP2018505205A (ja) 2018-02-22
AU2016219253A1 (en) 2017-09-21
ES2967643T3 (es) 2024-05-03
KR102601972B1 (ko) 2023-11-13
WO2016130796A1 (en) 2016-08-18
HUE058698T2 (hu) 2022-09-28
EP4046995C0 (en) 2023-09-13
UA122222C2 (uk) 2020-10-12
ES2911910T3 (es) 2022-05-23
MX371404B (es) 2020-01-29
EP3256466B9 (en) 2022-07-27
BR112017017354A2 (pt) 2018-04-10
JP2020079282A (ja) 2020-05-28
SG11201706515QA (en) 2017-09-28
EP3256466A1 (en) 2017-12-20
CY1125198T1 (el) 2024-12-13
CN107531674A (zh) 2018-01-02
JP6657241B2 (ja) 2020-03-04
EP3256466B1 (en) 2022-04-06
CA2976095A1 (en) 2016-08-18
MY188160A (en) 2021-11-24
MX2017010363A (es) 2018-05-04
SG10201806809QA (en) 2018-09-27
IL253914B (en) 2021-09-30
CN111925360B (zh) 2024-03-22
US9856238B2 (en) 2018-01-02
CN107531674B (zh) 2020-07-31
EP4046995B1 (en) 2023-09-13
EA201791804A1 (ru) 2018-02-28
ES2911910T9 (es) 2022-08-12
NZ735011A (en) 2023-07-28
US20220185799A1 (en) 2022-06-16
JP2022065050A (ja) 2022-04-26
US20190389845A1 (en) 2019-12-26
JP7023994B2 (ja) 2022-02-22
CA2976095C (en) 2023-10-17
PL3256466T3 (pl) 2022-05-23
AU2016219253B2 (en) 2020-10-01
US10336732B2 (en) 2019-07-02
IL253914A0 (en) 2017-10-31
EP4046995A1 (en) 2022-08-24
MX2020001157A (es) 2022-05-27

Similar Documents

Publication Publication Date Title
DK3224269T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3600270T3 (da) Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
DK3206493T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3250210T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
IL247452A0 (en) Compounds for treatment of complement mediated disorders
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
HUE058698T2 (hu) 1-heterociklusos izokromanil vegyületek és analógok a CNS rendellenességek kezelésére